Rwise. Stroke is an acute neurological Abiraterone 154229-19-3 event at least 24 h period is defined, with signs and symptoms of focal and best evidence without any other explanation Tion by computed tomography or magnetic resonance imaging CONFIRMS, or the Best Pathological confirmation support. Bleeding was defined in accordance with the criteria ACUITY trial, that the occurrence of the following: intracranial bleeding, retroperitoneal bleeding, intraocular bleeding, hemorrhage at the access point requires surgical or interventional radiological procedures, or the reduction of H hemoglobin concentration of 4 g / dl, reoperation for bleeding, or the use of blood products for transfusion. The secondary Ren endpoints were death and myocardial infarction, and the individual components of the primary Ren endpoint in one year. Stent thrombosis was a secondary Rer endpoint. Abciximab for comparison, was the prime Re endpoint composite of death, MI, TVR, and bleeding within 30 days. TVR was as a repeat PCI ish Chemistry driven Zielgef or bypass surgery of the Zielgef defines it. The target ship was like the whole boat severe coronary mission essential Defined. For the 30-day window, we have also investigated the occurrence of bleeding and stent thrombosis. Stent thrombosis was defined as definite or probable occurrence of a thrombotic event, such as the Academic Research Consortium classification. Statistics and data analysis. Analysis was by intention to treat.
We calculated that by 2427 patients in the stent-comparison in the study had 85% power a significant reduction in the primary Ren endpoint by 17% to 10% visible. Abciximab was to compare the study show a 80% performance to a significant decline in the primary Ren endpoint of 4% to 1% with 2424 patients. The statistical analysis was performed with SPSS. It is time to first event distributions have been as Kaplan-Meier curves and log-rank test applied used for comparison. Event rate after 30 days and 1 year were analyzed using Kaplan-Meier curves. We will present pr The Kaplan-Meier curves for global groups by randomization stent and abciximab randomization defined after testing best CONFIRMS the statistical assumptions of no interaction between the intervention and the intervention of the stent abciximab. Relative risks were calculated by dividing business of the Kaplan-Meier Tzten rate of one event in the abciximab group of SES or that calculated in the BMS or without abciximab group. The 95% confidence interval for the relative risk was calculated using the standard error of the Kaplan-Meier.
The significance of differences in event rates between treatment groups was with the log-rank test. Categorical variables were expressed as frequencies and were compared using chi-square or Fisher’s exact test, as appropriate. Continuous variables were expressed as means and standard deviations and were analyzed using a paired t-test or Mann-Whitney U-test. A two-tailed p value of 0.05 Fludarabine 21679-14-1 was shown to be statistically significant. Since the 30-day endpoints related to the abciximab randomization were different in the timing and mechanism of the endpoints of the 12 months in the stent randomized context, we have does not apply statistical corrections for multiple comparisons on the basis of the stent and abciximab randomization. Result.